# Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

> **NCT00741260** · PHASE1,PHASE2 · COMPLETED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 105 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Neratinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00741260
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-09
- **Primary completion:** 2010-11
- **Final completion:** 2018-06
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2018-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00741260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00741260, "Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00741260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*